PLC
AVIR icon

Peapod Lane Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Peapod Lane Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.44M Sell
272,820
-162,200
-37% -$745K 1.18% 39
2025
Q4 		$1.55M Sell
435,020
-22,196
-5% -$70.5K 1.32% 34
2025
Q3 		$1.33M Buy
457,216
+4,748
+1% +$16.2K 1.19% 40
2025
Q2 		$1.63M Buy
452,468
+408
+0.1% +$1.22K 1.63% 28
2025
Q1 		$1.35M Buy
452,060
+123,479
+38% +$385K 1.52% 26
2024
Q4 		$1.1M Buy
+328,581
New +$1.09M 1.09% 37

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Peapod Lane Capital's AVIR Position: Q1 2026 in Review

Peapod Lane Capital reduced its Atea Pharmaceuticals (AVIR) stake by 37% in Q1 2026, selling an estimated $745K and leaving 272,820 shares worth $1.44M. The position accounts for 1.18% of the portfolio, ranked #39.

Peapod Lane Capital first reported a position in AVIR in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.63M in Q2 2025. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Peapod Lane Capital held 272,820 shares of Atea Pharmaceuticals worth $1.44M as of Q1 2026.
  • Peapod Lane Capital sold 162,200 Atea Pharmaceuticals shares in Q1 2026, an estimated $745K.
  • Atea Pharmaceuticals made up 1.18% of Peapod Lane Capital's portfolio in Q1 2026, its #39 holding.
  • Peapod Lane Capital first reported a position in Atea Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Peapod Lane Capital's Atea Pharmaceuticals position peaked at $1.63M in Q2 2025.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Peapod Lane Capital's 13F filing for Q1 2026, filed 4 May 2026.